IMMUCELL CORPICCCEarnings & Financial Report
ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.
Revenue
$7.3M
Gross Profit
$2.3M
Operating Profit
$-300.1K
Net Profit
$-437.9K
Gross Margin
31.6%
Operating Margin
-4.1%
Net Margin
-6.0%
YoY Growth
110.6%
EPS
$-0.06
IMMUCELL CORP Q1 FY2024 Financial Summary
IMMUCELL CORP reported revenue of $7.3M (up 110.6% YoY) for Q1 FY2024, with a net profit of $-437.9K (up 81.1% YoY) (-6.0% margin). Cost of goods sold was $5.0M, operating expenses totaled $2.6M.
Key Financial Metrics
| Total Revenue | $7.3M |
|---|---|
| Net Profit | $-437.9K |
| Gross Margin | 31.6% |
| Operating Margin | -4.1% |
| Report Period | Q1 FY2024 |
IMMUCELL CORP Annual Revenue by Year
IMMUCELL CORP annual revenue history includes year-by-year totals (for example, 2024 revenue was $26.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $26.5M |
| 2023 | $17.5M |
IMMUCELL CORP Quarterly Revenue & Net Profit History
IMMUCELL CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $5.5M | -8.4% | $-139.7K | -2.5% |
| Q2 FY2025 | $6.4M | +17.8% | $501.9K | 7.8% |
| Q1 FY2025 | $8.1M | +11.2% | $1.4M | 17.9% |
| Q4 FY2024 | $7.8M | +52.1% | N/A | N/A |
| Q3 FY2024 | $6.0M | +11.4% | $-701.7K | -11.7% |
| Q2 FY2024 | $5.5M | +54.9% | $-1.5M | -28.0% |
| Q1 FY2024 | $7.3M | +110.6% | $-437.9K | -6.0% |
| Q4 FY2023 | $5.1M | — | N/A | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $7.3M | $5.5M | $6.0M | $7.8M | $8.1M | $6.4M | $5.5M |
| YoY Growth | N/A | 110.6% | 54.9% | 11.4% | 52.1% | 11.2% | 17.8% | -8.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $43.8M | $43.1M | $41.9M | $44.4M | $45.1M | $45.6M | $46.7M | $45.7M |
| Liabilities | $18.8M | $18.4M | $18.4M | $18.0M | $17.6M | $16.6M | $16.9M | $15.9M |
| Equity | $25.0M | $24.6M | $23.5M | $26.4M | $27.5M | $29.0M | $29.9M | $29.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-723071 | $418505 | $581780 | $-639331 | $-3051 | $1.6M | $1.6M | $-1.2M |